Target type: biologicalprocess
The process in which a relatively unspecialized cell acquires specialized features of a cardiac myoblast. A cardiac myoblast is a precursor cell that has been committed to a cardiac muscle cell fate but retains the ability to divide and proliferate throughout life. [GOC:dph, GOC:tb]
Cardiac muscle cell myoblast differentiation is a complex and tightly regulated process that involves a series of molecular events leading to the formation of mature, contractile cardiomyocytes. This process begins with the commitment of pluripotent stem cells or progenitor cells to a cardiac lineage, followed by a cascade of transcriptional and post-transcriptional events, signaling pathways, and changes in cell morphology and function.
1. **Commitment to Cardiac Lineage:** The initial step involves the expression of key transcription factors, including GATA4, NKX2.5, and MEF2C, which activate cardiac-specific genes and suppress genes associated with other cell lineages.
2. **Proliferation and Expansion:** Committed cardiac progenitor cells proliferate rapidly, increasing the pool of myoblasts available for differentiation. This phase is regulated by growth factors like fibroblast growth factor (FGF) and insulin-like growth factor (IGF).
3. **Myoblast Alignment and Fusion:** Myoblasts undergo a period of alignment and fusion, forming multinucleated syncytia called myotubes. This process is mediated by cell adhesion molecules, such as N-cadherin and integrins.
4. **Sarcomere Assembly and Contractile Machinery Formation:** Within the myotubes, sarcomeres, the basic contractile units of muscle, begin to assemble. Actin and myosin filaments, along with other structural proteins, are organized into a precise pattern, enabling coordinated contraction.
5. **Mitochondrial Biogenesis and Energy Production:** As myoblasts differentiate, there is a significant increase in mitochondrial biogenesis, providing the energy necessary for muscle contraction.
6. **Expression of Cardiac-Specific Proteins:** Mature cardiomyocytes express a unique set of proteins, including troponin, tropomyosin, and α-actinin, which are essential for muscle contraction and excitation-contraction coupling.
7. **Establishment of Gap Junctions and Electrical Coupling:** Gap junctions, specialized intercellular junctions, form between cardiomyocytes, allowing for the rapid propagation of electrical signals and coordinated contraction of the heart muscle.
8. **Maturation and Functional Integration:** Differentiated cardiomyocytes undergo further maturation, refining their contractile function and integrating into the complex network of the heart.
This intricate process is influenced by a variety of factors, including genetic predisposition, environmental signals, and the presence of specific growth factors and signaling molecules. The precise timing and regulation of these events are crucial for the proper development and function of the heart.'
"
Protein | Definition | Taxonomy |
---|---|---|
Neurogenic locus notch homolog protein 1 | A neurogenic locus notch homolog protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P46531] | Homo sapiens (human) |
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
calotropin | calotropin: structure in first source | cardenolide glycoside | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |